Nektar Therapeutics

US · NKTR #3017 by market cap Listed 1970

40.26 +0.35 +0.88%

Live - 5344 symbols - heartbeat 304s ago · 2026-10-08 06:54

Pre-market 39.35 -2.26%

After-hours 40.00 -0.65%

Overnight 40.20 -0.15%

Market cap: 1.37B
P/E (TTM): -6.58
P/B: 1.52
EPS: -9.73
Div yield: 0.00%
52W pos: 9%

Reader sentiment Are you bullish or bearish on NKTR?

Anonymous reader poll. Unscientific, not investment advice.

About Nektar Therapeutics

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Founded: 1990
CEO: Mr. Howard W. Robin
Employees: 63
Headquarters: San Francisco, California, United States of America
Fiscal year end: 12-31
Website: nektar.com

Company profile

Exchange: US
Symbol: NKTR
Market-cap rank: #3017
Listing date: 1970-01-01
Market cap: 1.37B
Float cap: 1.14B
Shares out: 34.14M
Float shares: 28.28M

Sectors & themes

Biotechnology

Browse all sectors & themes

Quote time 2026-10-08 06:54:04 · For reference only, not investment advice and not tailored to your situation.